Atlas Trials

SHR-4602 for Injection in Subjects With HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors

Clinical trial NCT06516926 · TERMINATED

Trial details

NCT number
NCT06516926
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors
Start date
2024-08-08
Primary completion
2025-05-23
Enrollment
11

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.